| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.84 [0.55, 1.27] | | < 1 | | 86% | 2 studies (2/-) | 79.4 % | low | not evaluable | high | crucial | - |
| DOR | 0.68 [0.55, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.28 [0.16, 9.97] | | > 1 | | 85% | 2 studies (2/-) | 59.1 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.96 [0.79, 4.84] | | < 1 | | 0% | 2 studies (2/-) | 7.4 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 0.97 [0.73, 1.28] | | < 1 | | 0% | 2 studies (2/-) | 59.5 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 2.08 [1.43, 3.03] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.36 [0.91, 2.04] | | < 1 | | 0% | 2 studies (2/-) | 6.7 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.36 [0.28, 6.47] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.39 [0.15, 12.46] | | < 1 | | 0% | 2 studies (2/-) | 38.6 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 1.58 [0.12, 20.33] | | < 1 | | 68% | 2 studies (2/-) | 36.4 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.59 [0.28, 9.13] | | < 1 | | 61% | 2 studies (2/-) | 30.1 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.59 [0.07, 5.18] | | < 1 | | 51% | 2 studies (2/-) | 68.2 % | low | not evaluable | high | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 2.03 [0.20, 20.30] | | < 1 | | 79% | 2 studies (2/-) | 27.6 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.69 [0.06, 7.66] | | < 1 | | 0% | 2 studies (2/-) | 61.7 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 0.71 [0.16, 3.24] | | < 1 | | 12% | 2 studies (2/-) | 67.0 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.51 [0.10, 2.70] | | < 1 | | 0% | 2 studies (2/-) | 78.5 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.69 [0.06, 7.66] | | < 1 | | 0% | 2 studies (2/-) | 61.7 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 0.27 [0.04, 1.95] | | < 1 | | 0% | 2 studies (2/-) | 90.1 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.39 [0.15, 12.46] | | < 1 | | 0% | 2 studies (2/-) | 38.6 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 0.69 [0.06, 7.66] | | < 1 | | 0% | 2 studies (2/-) | 61.7 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 2.22 [0.39, 12.59] | | < 1 | | 0% | 2 studies (2/-) | 18.4 % | low | not evaluable | high | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 2.15 [0.55, 8.37] | | < 1 | | 0% | 2 studies (2/-) | 13.5 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.35 [0.02, 5.54] | | < 1 | | 0% | 2 studies (2/-) | 77.1 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.47 [0.14, 1.62] | | < 1 | | 40% | 2 studies (2/-) | 88.3 % | low | not evaluable | high | non important | - |
| Anaemia AE (grade 3-4) | 0.52 [0.18, 1.45] | | < 1 | | 52% | 2 studies (2/-) | 89.5 % | low | not evaluable | high | non important | - |
| Constipation AE (grade 3-4) | 0.49 [0.13, 1.84] | | < 1 | | 0% | 2 studies (2/-) | 85.3 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 0.69 [0.06, 7.66] | | < 1 | | 0% | 2 studies (2/-) | 61.7 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 0.67 [0.25, 1.84] | | < 1 | | 0% | 2 studies (2/-) | 78.0 % | low | not evaluable | high | non important | - |
| Diarrhoea AE (grade 3-4) | 1.82 [0.27, 12.37] | | < 1 | | 68% | 2 studies (2/-) | 27.1 % | low | not evaluable | high | non important | - |
| Dyspnoea AE (grade 3-4) | 0.87 [0.43, 1.78] | | < 1 | | 0% | 2 studies (2/-) | 64.3 % | low | not evaluable | high | non important | - |
| Fatigue AE (grade 3-4) | 1.01 [0.44, 2.31] | | < 1 | | 34% | 2 studies (2/-) | 48.9 % | low | not evaluable | high | non important | - |
| Headache AE (grade 3-4) | 0.46 [0.16, 1.33] | | < 1 | | 0% | 2 studies (2/-) | 92.5 % | low | not evaluable | high | non important | - |
| Nausea AE (grade 3-4) | 0.69 [0.26, 1.85] | | < 1 | | 0% | 2 studies (2/-) | 77.1 % | low | not evaluable | high | non important | - |
| Pyrexia AE (grade 3-4) | 0.51 [0.10, 2.71] | | < 1 | | 0% | 2 studies (2/-) | 78.4 % | low | not evaluable | high | non important | - |
| Vomiting AE (grade 3-4) | 0.80 [0.31, 2.11] | | < 1 | | 0% | 2 studies (2/-) | 67.1 % | low | not evaluable | high | non important | - |
